Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia
dc.contributor.author | Perrotti, Danilo | |
dc.contributor.author | Agarwal, Anupriya | |
dc.contributor.author | Lucas, Claire | |
dc.contributor.author | Narla, Goutham | |
dc.contributor.author | Nevanini, Paolo | |
dc.contributor.author | Odero, Maria D. | |
dc.contributor.author | Ruvolo, Peter P. | |
dc.contributor.author | Verrills, Nicole M. | |
dc.date.accessioned | 2021-03-24T09:23:37Z | |
dc.date.available | 2021-03-24T09:23:37Z | |
dc.date.issued | 2019-07-17 | |
dc.identifier.citation | Perrotti, D., Agarwal, A., Lucas, C. M., Narla, G., Neviani, P., Odero, M. D., ... & Verrills, N. M. (2019). Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”. Science translational medicine, 11(501), eaau0416. https://doi.org/10.1126/scitranslmed.aau0416 | en_US |
dc.identifier.issn | 1946-6234 | |
dc.identifier.doi | 10.1126/scitranslmed.aau0416 | |
dc.identifier.uri | http://hdl.handle.net/10034/624385 | |
dc.description | This article is not available on ChesterRep. | |
dc.description.abstract | LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis. | en_US |
dc.language.iso | en | en_US |
dc.publisher | American Association for the Advancement of Science | en_US |
dc.relation.url | https://www.science.org/doi/10.1126/scitranslmed.aau0416 | |
dc.rights | CC0 1.0 Universal | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | PP2A | en_US |
dc.subject | LB100 | en_US |
dc.subject | CML | en_US |
dc.subject | LEUKAEMIA | en_US |
dc.title | Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1946-6242 | en_US |
dc.contributor.department | University of Maryland; Imperial College London; Oregon Health and Science University; University of Chester; University of Michigan; University of Southern California; University of Navarra; MD Anderson Cancer Center; University of Newcastle | en_US |
dc.identifier.journal | Science Translational Medicine | en_US |
dc.date.accepted | 2019-05-09 | |
or.grant.openaccess | Yes | en_US |
rioxxterms.funder | n/a | en_US |
rioxxterms.identifier.project | n/a | en_US |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1126/scitranslmed.aau0416 | en_US |
rioxxterms.licenseref.startdate | 2221-07-17 | |
dcterms.dateAccepted | 2019-06-17 | |
rioxxterms.publicationdate | 2019-07-17 | |
dc.date.deposited | 2021-03-24 | en_US |
dc.indentifier.issn | 1946-6234 | en_US |